All News
Expanding the IL-17 Therapeutic Landscape
IL-17 inhibitors are an effective therapeutic for a broad spectrum of inflammatory and autoimmune diseases and its blockade has revolutionized management of diseases such as psoriasis, psoriatic arthritis and SpA. Is there a need for more medications within the same therapeutic class?
Read Article
Social Determinants of Health in SLE
EurekAlert!
Social determinants of health (SDH), such as socioeconomic status and educational background are factors that are increasingly recognised as critical contributors to health outcomes in chronic diseases.
Read Article
Should we screen for #lung #cancer in #SSc high risk Pts? When >10 yrs?
Greek cohort of SSc since 1995
Disease duration 12 yrs,
smoking lung ca group ⬆️58% vs 29%
⬆️dcSSc
⬆️immunosuppression
OR >4X lung ca if dcSSc, IS
Less #DU
#PO0940 @RheumNow @eular_org #EULAR2025 https://t.co/L2zEkP8pAc
Links:
Janet Pope Janetbirdope ( View Tweet)
Some RA-ILD is less of a worry, some is critical. How do we stratify?
Great modelling work from Korea & @jeffsparks - model stratifying really well, even without KL-6.
We need to do this more, so we can go really hard early when we need to.
#EULAR2025 OP0329 @RheumNow https://t.co/i2djatO3F2
David Liew drdavidliew ( View Tweet)
🌍Patients w RMDs across 🇫🇷🇳🇱🇨🇭🇹🇷 face different barriers to physical activity:
💶Cost =barrier in 🇳🇱
⛈️Weather =barrier in 🇹🇷
🧑⚕️HCP support =key in 🇫🇷
🏃Active transport & knowledge =enablers in 🇨🇭
Tailored physical activity interventions needed.
@RheumNow #EULAR2025 #OP0382-HPR https://t.co/lk7fwDHDe7
Mrinalini Dey DrMiniDey ( View Tweet)
PsO + recent arthralgia—but no PsA. Treat or wait?
🧠 18% developed PsA in 3 yrs, most in year 1
🔍 Predictors: tender joints, disability, enthesis erosion
Consider early rheum input for these patients
Abstract POS0299 @RheumNow #EULAR2025
Jiha Lee JihaRheum ( View Tweet)
Very pleased to present at #EULAR2025 work @ArthritisAust on consumer involvement into research.
Consumer involvement in research delivers:
- better, more relevant research
- better dissemination of results
- competitiveness in today’s funding landscape
POS1016-PARE @RheumNow https://t.co/0fhpsnGhdT
David Liew drdavidliew ( View Tweet)
Maybe the pathogenesis gives us a clue on how to target things?
Possibly the treatments which take down synovitis might not always help with nodules
Christopher Edwards #EULAR2025 @RheumNow https://t.co/T6QHCS8709
Links:
David Liew drdavidliew ( View Tweet)
What is new in SpA?
‼️nomenclature change:
🚫AS≠ Ankylosing spondylitis
✅AS= Axial spondyloarthritis
-Helena Marzo-Ortega at #EULAR2025
@RheumNow
Adela Castro AdelaCastro222 ( View Tweet)
Delay hurts.
Dx delay in axial SpA costs UK £3.1 billion annually.
Avg time to dx = 8.5 yrs
Avg dx cost = £187k/person
Fixing delay could save £167k/person.
Early Dx isn’t just better care—it’s economic policy.
#EULAR2025 @RheumNow
#AxialSpA #RMD https://t.co/eYEQ2rp94m
Jiha Lee JihaRheum ( View Tweet)
#EULAR2025 Abstr#OP0324 Cohort study of #lupus nephritis in Greece showed Earlier GC Discontinuation (D/C) & flare protection post-D/C is associated with renal response, low disease activity & HCQ use at GC D/C. Membranous LN & recent diagnosis were assoc w early GC D/C @RheumNow https://t.co/agFgyG5eaS
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
About #Multidisciplinarity ...
Dr Ihsane Hmamouchi talking about Multidisciplinary Approach to Migrant #Rheumatology Care
#quotes
#EULAR2025
#Invitedspeaker
#outofthebox
@RheumNow
@epirheum https://t.co/RG6xpHejv9
Nelly ZIADE 🍀 Nellziade ( View Tweet)
RheumNow’s expanded coverage of the #EULAR2025 Annual meeting is sponsored in part by Johnson & Johnson and UCB. All content chosen by RheumNow & its Faculty
Dr. John Cush RheumNow ( View Tweet)
Diagnostic delay in #SpA
🔹️Data from the @Official_ASAS
Study
🔹️4339 patients
🔹️Delay was 6.6 years
🔹️Longer in axSpA and IBD-SpA, shorter in PsA and pSpA
🔹️Associated with type of initial symptoms (shorter in peripheral)
POS0909 #EULAR2025
@rheumnow https://t.co/3BMYFxbKiq
Nelly ZIADE 🍀 Nellziade ( View Tweet)
#ANCA #vasculitis is not created equally
REVEAL cohort 588 ANCA
Initial & 12 months #BVAS (activity index)
mean ⬇️BVAS over 1 yr in all groups
#GPA #MPA #eGPA
5yr survival not = over time
⬆️survival in eGPA & GPA vs MPA
#POS0329 #EULAR2025 @RheumNow @eular_org https://t.co/cUKytqNZnS
Links:
Janet Pope Janetbirdope ( View Tweet)
Is RA just one disease?
No, & increasingly more efforts to subgroup RA on diff levels
Simple approach - derived phenotypes map (independent of ACPA):
- to broad histopath
- to MTX response
Omics is good, but still need to do the simple stuff better!
#EULAR2025 OP0328 @RheumNow https://t.co/a8Vl7Kcjso
David Liew drdavidliew ( View Tweet)
RheumNow’s expanded coverage of the #EULAR2025 Annual meeting is sponsored in part by Johnson & Johnson and UCB. All content chosen by RheumNow & its faculty.
Dr. John Cush RheumNow ( View Tweet)
Live Daily Eular 2025 Recap Day 1 https://t.co/dLV83VcGuC
Links:
Dr. John Cush RheumNow ( View Tweet)
Worth mentioning: the type of monoclonal protein is important for diagnosis. Different diseases with different therapies #EULAR2025 @RheumNow l https://t.co/5bbQnHV6CI
David Liew drdavidliew ( View Tweet)
#vagal & #splenic #nerves most studied
In #immune #system interaction
#PNS can detect #inflammation
use in #D2T #RA w active disease ?
Key factors in #neurostimulation - many
#EULAR2025 @RheumNow @eular_org
#D2T in #RA session https://t.co/tCgpGtI5z2
Links:
Janet Pope Janetbirdope ( View Tweet)
